Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Open-label study of s-citalopram therapy of chronic fatigue syndrome and co-morbid major depressive disorder
OBJECTIVE Chronic fatigue syndrome ( CFS ) is a debilitating disorder with prominent symptoms of malaise , fatigue , myalgia , arthralgia , and impaired concentration . The symptoms of CFS may often overlap those of Major Depressive Disorder ( MDD ) . Treatment of CFS has generally been disappointing . We hypothesized that s-citalopram therapy may improve the symptoms of both disorders in CFS patients with co-morbid depression . METHODS 16 patients received s-citalopram 10 mg to 20 mg daily for up to 12 weeks . Outcome measures of CFS included the Chalder Fatigue Question naire ( CFQ ) , the multi-dimensional Fatigue Impact Scale ( FIS ) , the CFS symptom rating ( CFS-SR ) 100 mm visual analogue scale , and the clinical global impressions severity ( CGI/S ) and change ( CGI/C ) ratings . Secondary outcomes of MDD included the Hamilton Depression Rating ( HAM-D ) , Beck Depression Inventory ( BDI ) , and the CGI/S and CGI/C ratings of MDD . RESULTS We observed reductions in the mean CFQ score ( p<0.0005 ) , FIS score ( p<0.0005 ) , and CGI/S ( p<0.0005 ) and CGI/C ( p<0.0005 ) ratings over time . There was a significant improvement in 5 of the 8 CFS-SR symptoms : post-exertion malaise ( p=0.001 ) , headaches ( p<0.0005 ) , un-refreshing sleep ( p<0.0005 ) , and impaired memory and concentration ( p<0.0005 ) . There was also a reduction in mean HAM-D ( p<0.0005 ) , BDI ( p<0.0005 ) , CGI/S ( p=0.001 ) and CGI/C ( p<0.0005 ) ratings of MDD . LIMITATIONS The sample size was limited and the study design was not double-blind or placebo controlled . CONCLUSION We observed a significant reduction in both CFS and co-morbid MDD symptom severity ratings , and improvement in 5 of 8 core somatic symptoms of CFS during s-citalopram therapy
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .